|Day Low/High||5.56 / 5.85|
|52 Wk Low/High||3.43 / 19.80|
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Galena Biopharma Inc , where a total of 10,365 contracts have traded so far, representing approximately 1.0 million underlying shares. That amounts to about 66.9% of GALE's average daily trading volume over the past month of 1.5 million shares.
Issued Patent Will Cover Multiple Additional Claims Around the Use of NeuVax
Data Confirms Patient Population Eligibility for Planned Phase 2 Clinical Study of NeuVax™ (nelipepimut-S) in Gastric Cancer to be Conducted in Partnership With Dr. Reddy's Laboratories Ltd.
Company Enters 2016 With Focus on Immuno-Oncology Clinical Pipeline
I'm only making one big prediction this year: The five-year party which saw biotech stocks outperform the broader markets comes to an end in 2016.
Zuplenz to be Sold to Midatech Pharma Plc for a Potential of $23.65 Million Net Payable to Galena Biopharma
Total Transaction Value of Up to $12 Million With $8 Million Cash Upfront and an Additional $4 Million Based on Achievement of Certain Sales Milestones
Galena Biopharma (GALE) stock was upgraded to 'outperform' from 'perform' at Oppenheimer on Thursday.
Galena Biopharma (GALE) stock is falling on Tuesday after the company reported a 2015 third quarter earnings loss that was wider than analysts expected.
Clinical Trial Expected to Initiate in Q4, 2015
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.